Anaptysbio Inc (ANAB)

$57.87 +2.40 (4.33%)
Market Cap 1.64B
Revenue (ttm) 234.60M
Net Income (ttm) -13.23M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -5.64%
Debt to Equity Ratio 0.00
Volume 372,000
Avg Vol 662,296
Day's Range N/A - N/A
Shares Out 29.61M
Stochastic %K 84%
Beta 0.72
Analysts Strong Sell
Price Target $87.09

Company Profile

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company's products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phas...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 362 6295
Address:
10770 Wateridge Circle, Suite 210, San Diego, United States
StockBraker
StockBraker Aug. 12 at 10:46 AM
$ANAB Estimated ER date is today AH. Estimated EPS Forecast: -$0.13 to -$0.22. PREVIOUS Report: Released Q1 2026 results on May 12, 2026, with an EPS of -$1.84. Last quarter they completed spin-off of First Tracks Biotherapeutics, Inc., its former biopharma operations business. Now exclusively manages the financial collaborations for Jemperli with GSK and imsidolimab with Vanda. Personally looking for $100+/share LT. Those that have held for awhile have definitely benefited from the spinoff. BTW - If you need to know your cost basis for each company (ANAB, TRAX) for tax purposes you can either use what your broker states or Form 8937 (https://ir.anaptysbio.com/irs-form-8937)
0 · Reply
Ramod
Ramod Aug. 7 at 12:35 PM
$ANAB I’m In
0 · Reply
StockBraker
StockBraker Aug. 5 at 2:13 PM
$TRAX $ANAB Need to break through the $105 combined price ceiling. I hate this overhang from the Tesaro lawsuit. Legal processes move too slow.
0 · Reply
Jt11111
Jt11111 Jul. 29 at 6:22 PM
$TRAX $ANAB solid Jemperil sales from gsk —$320MM keep ANAB royalty on track and this is a steal at $50. 1. H1 2026 Actual Sales (First Half) Q1 2026: £232 million ($313 million USD) Q2 2026: £248 million ($320 million USD) Total H1 2026: £480 million GBP (~$620 million USD)
1 · Reply
Jt11111
Jt11111 Jul. 29 at 3:21 PM
$ANAB solid Jemperil sales from gsk —$320MM keep royalty on track and this is a steal at $50. 1. H1 2026 Actual Sales (First Half) Q1 2026: £232 million ($313 million USD) Q2 2026: £248 million ($320 million USD) Total H1 2026: £480 million GBP (~$620 million USD)
0 · Reply
Nickman18
Nickman18 Jul. 27 at 2:23 PM
$ANAB $TRAX I've owned since 2019 with a price average of 20.66 just wanted to brag quickly
1 · Reply
JackDarwin
JackDarwin Jul. 22 at 10:51 AM
$ANAB Bullish Marubozu with good volume.
0 · Reply
StockBraker
StockBraker Jul. 20 at 8:16 PM
$ANAB Guess I need to do this again. Collected $1048 premium and kept my shares.
0 · Reply
StockBraker
StockBraker Jul. 20 at 8:06 PM
$ANAB marketbeat.com/instant-alerts/anaptysbio-nasdaqanab-shares-down-62-heres-why-2026-07-20/
0 · Reply
Jt11111
Jt11111 Jul. 20 at 6:17 PM
$ANAB wtf
0 · Reply
Latest News on ANAB
AnaptysBio falls -10.8%

2026-07-15T14:05:42.000Z - 27 days ago

AnaptysBio falls -10.8%

AnaptysBio Proxy statement: Proxy filing

Jun 29, 2026, 8:00 AM EDT - 6 weeks ago

AnaptysBio Proxy statement: Proxy filing

AnaptysBio Proxy statement: Proxy filing

Jun 29, 2026, 8:00 AM EDT - 6 weeks ago

AnaptysBio Proxy statement: Proxy filing

AnaptysBio assumed with a Buy at H.C. Wainwright

2026-06-10T10:19:07.000Z - 2 months ago

AnaptysBio assumed with a Buy at H.C. Wainwright

AnaptysBio price target raised to $90 from $85 at Leerink

2026-05-15T16:45:33.000Z - 3 months ago

AnaptysBio price target raised to $90 from $85 at Leerink

GSK

AnaptysBio price target raised to $76 from $60 at UBS

2026-05-13T12:17:45.000Z - 3 months ago

AnaptysBio price target raised to $76 from $60 at UBS

AnaptysBio price target raised to $75 from $63 at Barclays

2026-05-13T09:01:49.000Z - 3 months ago

AnaptysBio price target raised to $75 from $63 at Barclays

AnaptysBio reports Q1 EPS ($1.84), consensus (75c)

2026-05-12T20:47:39.000Z - 3 months ago

AnaptysBio reports Q1 EPS ($1.84), consensus (75c)

Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update

May 12, 2026, 4:15 PM EDT - 3 months ago

Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update

AnaptysBio Earnings release: Q1 2026

May 12, 2026, 4:00 PM EDT - 3 months ago

AnaptysBio Earnings release: Q1 2026

AnaptysBio Quarterly report: Q1 2026

May 12, 2026, 4:00 PM EDT - 3 months ago

AnaptysBio Quarterly report: Q1 2026

AnaptysBio appoints Christopher Murphy as CFO

2026-05-11T20:06:02.000Z - 3 months ago

AnaptysBio appoints Christopher Murphy as CFO

Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors

May 11, 2026, 9:15 AM EDT - 3 months ago

Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors

Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference

May 4, 2026, 4:15 PM EDT - 3 months ago

Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference

AnaptysBio price target lowered to $93 from $95 at Piper Sandler

2026-05-04T11:53:49.000Z - 3 months ago

AnaptysBio price target lowered to $93 from $95 at Piper Sandler

GSK TRAX VNDA

Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence

Apr 28, 2026, 7:12 PM EDT - 3 months ago

Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence

VNDA

AnaptysBio price target raised to $85 from $66 at Leerink

2026-04-28T10:29:57.000Z - 3 months ago

AnaptysBio price target raised to $85 from $66 at Leerink

GSK’s TESARO provides update on AnaptysBio litigation

2026-04-27T10:41:58.000Z - 3 months ago

GSK’s TESARO provides update on AnaptysBio litigation

GSK

Delaware court dismisses Tesaro breach of contract claim against AnaptysBio

2026-04-24T19:50:20.000Z - 3 months ago

Delaware court dismisses Tesaro breach of contract claim against AnaptysBio

GSK

Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro's Anticipatory Breach Claim

Apr 24, 2026, 3:40 PM EDT - 3 months ago

Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro's Anticipatory Breach Claim

AnaptysBio price target lowered to $60 from $90 at UBS

2026-04-22T13:52:10.000Z - 3 months ago

AnaptysBio price target lowered to $60 from $90 at UBS

AnaptysBio price target lowered to $63 from $79 at Barclays

2026-04-22T09:36:10.000Z - 4 months ago

AnaptysBio price target lowered to $63 from $79 at Barclays

AnaptysBio price target lowered to $60 from $90 at UBS

2026-04-21T13:14:24.000Z - 4 months ago

AnaptysBio price target lowered to $60 from $90 at UBS

GSK VNDA

AnaptysBio completes separation of First Tracks Biotherapeutics

2026-04-20T15:31:29.000Z - 4 months ago

AnaptysBio completes separation of First Tracks Biotherapeutics

Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations

Apr 20, 2026, 9:15 AM EDT - 4 months ago

Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations

AnaptysBio price target raised to $95 from $67 at Piper Sandler

2026-03-31T10:51:07.000Z - 4 months ago

AnaptysBio price target raised to $95 from $67 at Piper Sandler

AnaptysBio announces $100M share repurchase program

2026-03-27T13:13:30.000Z - 4 months ago

AnaptysBio announces $100M share repurchase program

AnaptysBio board approves spin-off of First Tracks Biotherapeutics

2026-03-27T13:06:05.000Z - 4 months ago

AnaptysBio board approves spin-off of First Tracks Biotherapeutics

Anaptys Board of Directors Approves Spin-Off of First Tracks Biotherapeutics

Mar 27, 2026, 9:00 AM EDT - 4 months ago

Anaptys Board of Directors Approves Spin-Off of First Tracks Biotherapeutics

Anaptys Announces $100 Million Stock Repurchase Plan and Provides a Business Update

Mar 27, 2026, 9:00 AM EDT - 4 months ago

Anaptys Announces $100 Million Stock Repurchase Plan and Provides a Business Update

First Tracks Biotherapeutics, the Planned Spin-Off of Anaptys, Secures Commitments of $145 Million in Private Placement

Mar 27, 2026, 9:00 AM EDT - 4 months ago

First Tracks Biotherapeutics, the Planned Spin-Off of Anaptys, Secures Commitments of $145 Million in Private Placement

AnaptysBio price target raised to $90 from $70 at UBS

2026-03-17T10:45:14.000Z - 5 months ago

AnaptysBio price target raised to $90 from $70 at UBS

AnaptysBio Transcript: Leerink Global Healthcare Conference 2026

Mar 11, 2026, 2:20 PM EDT - 5 months ago

AnaptysBio Transcript: Leerink Global Healthcare Conference 2026

AnaptysBio Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 10, 2026, 8:30 AM EDT - 5 months ago

AnaptysBio Transcript: Barclays 28th Annual Global Healthcare Conference

AnaptysBio Transcript: TD Cowen 46th Annual Health Care Conference

Mar 4, 2026, 11:50 AM EST - 5 months ago

AnaptysBio Transcript: TD Cowen 46th Annual Health Care Conference

Anaptys Provides Update on Business Separation and Announces Fourth Quarter and Full Year 2025 Financial Results

Mar 3, 2026, 4:15 PM EST - 5 months ago

Anaptys Provides Update on Business Separation and Announces Fourth Quarter and Full Year 2025 Financial Results

AnaptysBio Annual report: Q4 2025

Mar 3, 2026, 4:00 PM EST - 5 months ago

AnaptysBio Annual report: Q4 2025

AnaptysBio Earnings release: Q4 2025

Mar 3, 2026, 4:00 PM EST - 5 months ago

AnaptysBio Earnings release: Q4 2025

AnaptysBio Slides: Corporate presentation

Mar 2, 2026, 6:00 AM EST - 5 months ago

AnaptysBio Slides: Corporate presentation

Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis

Feb 25, 2026, 7:18 AM EST - 5 months ago

Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis

VNDA

AnaptysBio Transcript: Piper Sandler Virtual Novel Targets in Immunology Symposium

Feb 12, 2026, 1:00 PM EST - 6 months ago

AnaptysBio Transcript: Piper Sandler Virtual Novel Targets in Immunology Symposium

AnaptysBio Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 11, 2026, 3:00 PM EST - 6 months ago

AnaptysBio Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Anaptys Announces Participation at Upcoming Investor Conferences

Feb 5, 2026, 4:15 PM EST - 6 months ago

Anaptys Announces Participation at Upcoming Investor Conferences

AnaptysBio Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 7:30 PM EST - 7 months ago

AnaptysBio Transcript: 44th Annual J.P. Morgan Healthcare Conference

AnaptysBio Slides: Corporate presentation

Jan 9, 2026, 7:00 AM EST - 7 months ago

AnaptysBio Slides: Corporate presentation

AnaptysBio seeks partial dismissal in GSK oncology unit dispute over drug royalty

Jan 8, 2026, 7:09 PM EST - 7 months ago

AnaptysBio seeks partial dismissal in GSK oncology unit dispute over drug royalty

GSK

Anaptys Files Motion to Dismiss Tesaro's Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary

Jan 8, 2026, 6:00 PM EST - 7 months ago

Anaptys Files Motion to Dismiss Tesaro's Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary

Anaptys to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 6, 2026, 4:15 PM EST - 7 months ago

Anaptys to Present at the 44th Annual J.P. Morgan Healthcare Conference

Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis

Dec 15, 2025, 7:00 AM EST - 8 months ago

Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis

VNDA

AnaptysBio Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 3, 2025, 7:55 AM EST - 8 months ago

AnaptysBio Transcript: Evercore ISI 8th Annual HealthCONx Conference

AnaptysBio Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 2, 2025, 1:30 PM EST - 9 months ago

AnaptysBio Transcript: Piper Sandler 37th Annual Healthcare Conference

Anaptys Announces Participation in December Investor Conferences

Nov 25, 2025, 4:15 PM EST - 9 months ago

Anaptys Announces Participation in December Investor Conferences

AnaptysBio shares tumble after legal fight with GSK over cancer drug license

Nov 21, 2025, 8:52 AM EST - 9 months ago

AnaptysBio shares tumble after legal fight with GSK over cancer drug license

GSK

GSK, AnaptysBio Sue Each Other Over Cancer Drug License

Nov 21, 2025, 6:14 AM EST - 9 months ago

GSK, AnaptysBio Sue Each Other Over Cancer Drug License

GSK

Anaptys Announces $100 Million Stock Repurchase Plan

Nov 21, 2025, 4:00 AM EST - 9 months ago

Anaptys Announces $100 Million Stock Repurchase Plan

Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary

Nov 21, 2025, 3:50 AM EST - 9 months ago

Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary

GSK

AnaptysBio Transcript: Jefferies London Healthcare Conference 2025

Nov 17, 2025, 11:00 AM EST - 9 months ago

AnaptysBio Transcript: Jefferies London Healthcare Conference 2025

AnaptysBio Transcript: Stifel 2025 Healthcare Conference

Nov 13, 2025, 1:20 PM EST - 9 months ago

AnaptysBio Transcript: Stifel 2025 Healthcare Conference

AnaptysBio Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 12, 2025, 11:30 AM EST - 9 months ago

AnaptysBio Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

AnaptysBio Transcript: TD Cowen Immunology and Inflammation Summit

Nov 12, 2025, 8:00 AM EST - 9 months ago

AnaptysBio Transcript: TD Cowen Immunology and Inflammation Summit

AnaptysBio Slides: Corporate Presentation

Nov 10, 2025, 6:00 PM EST - 9 months ago

AnaptysBio Slides: Corporate Presentation

Anaptys Announces Phase 2 Trial of Rosnilimab Did Not Meet Primary or Secondary Endpoints at Week 12 in Moderate-to-Severe Ulcerative Colitis

Nov 10, 2025, 9:00 AM EST - 9 months ago

Anaptys Announces Phase 2 Trial of Rosnilimab Did Not Meet Primary or Secondary Endpoints at Week 12 in Moderate-to-Severe Ulcerative Colitis

Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update

Nov 4, 2025, 4:15 PM EST - 10 months ago

Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update

Anaptys Announces Participation in November Investor Conferences

Nov 4, 2025, 4:15 PM EST - 10 months ago

Anaptys Announces Participation in November Investor Conferences

AnaptysBio Quarterly report: Q3 2025

Nov 4, 2025, 3:00 PM EST - 10 months ago

AnaptysBio Quarterly report: Q3 2025

AnaptysBio Earnings release: Q3 2025

Nov 4, 2025, 3:00 PM EST - 10 months ago

AnaptysBio Earnings release: Q3 2025

Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation

Oct 29, 2025, 9:15 AM EDT - 10 months ago

Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation

AnaptysBio Transcript: Status Update

Oct 14, 2025, 4:30 PM EDT - 10 months ago

AnaptysBio Transcript: Status Update

AnaptysBio Slides: Status Update

Oct 14, 2025, 4:30 PM EDT - 10 months ago

AnaptysBio Slides: Status Update

Anaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025

Oct 13, 2025, 9:15 AM EDT - 10 months ago

Anaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025

AnaptysBio Transcript: Investor Update

Sep 29, 2025, 4:30 PM EDT - 11 months ago

AnaptysBio Transcript: Investor Update

AnaptysBio Press release: Investor Update

Sep 29, 2025, 4:30 PM EDT - 11 months ago

AnaptysBio Press release: Investor Update

AnaptysBio Slides: Investor Update

Sep 29, 2025, 4:30 PM EDT - 11 months ago

AnaptysBio Slides: Investor Update

Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026

Sep 29, 2025, 4:05 PM EDT - 11 months ago

Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026

Anaptys to Provide Overview of ANB033, a CD122 antagonist, at Virtual Investor Event on Tuesday, Oct. 14

Sep 29, 2025, 4:05 PM EDT - 11 months ago

Anaptys to Provide Overview of ANB033, a CD122 antagonist, at Virtual Investor Event on Tuesday, Oct. 14

AnaptysBio Slides: Corporate Presentation

Sep 29, 2025, 7:00 AM EDT - 11 months ago

AnaptysBio Slides: Corporate Presentation

AnaptysBio Transcript: Stifel Virtual Immunology and Inflammation Forum

Sep 16, 2025, 12:00 PM EDT - 11 months ago

AnaptysBio Transcript: Stifel Virtual Immunology and Inflammation Forum

AnaptysBio Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 4, 2025, 11:00 AM EDT - 1 year ago

AnaptysBio Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

AnaptysBio Transcript: Cantor Global Healthcare Conference 2025

Sep 3, 2025, 8:00 AM EDT - 1 year ago

AnaptysBio Transcript: Cantor Global Healthcare Conference 2025

Anaptys Announces Participation in September Investor Conferences

Aug 27, 2025, 4:15 PM EDT - 1 year ago

Anaptys Announces Participation in September Investor Conferences

Anaptys Announces Second Quarter 2025 Financial Results and Provides Business Update

Aug 6, 2025, 4:15 PM EDT - 1 year ago

Anaptys Announces Second Quarter 2025 Financial Results and Provides Business Update

AnaptysBio Quarterly report: Q2 2025

Aug 6, 2025, 4:00 PM EDT - 1 year ago

AnaptysBio Quarterly report: Q2 2025

AnaptysBio Earnings release: Q2 2025

Aug 6, 2025, 4:00 PM EDT - 1 year ago

AnaptysBio Earnings release: Q2 2025

AnaptysBio Slides: Corporate Presentation

Jun 16, 2025, 7:00 AM EDT - 1 year ago

AnaptysBio Slides: Corporate Presentation

AnaptysBio Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 11, 2025, 8:40 AM EDT - 1 year ago

AnaptysBio Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

AnaptysBio Transcript: Jefferies Global Healthcare Conference 2025

Jun 5, 2025, 8:45 AM EDT - 1 year ago

AnaptysBio Transcript: Jefferies Global Healthcare Conference 2025

AnaptysBio Slides: FY 2025

Jun 5, 2025, 8:45 AM EDT - 1 year ago

AnaptysBio Slides: FY 2025

AnaptysBio Transcript: Status Update

Jun 3, 2025, 4:15 PM EDT - 1 year ago

AnaptysBio Transcript: Status Update

AnaptysBio Press release: Status Update

Jun 3, 2025, 4:15 PM EDT - 1 year ago

AnaptysBio Press release: Status Update

AnaptysBio Slides: Status Update

Jun 3, 2025, 4:15 PM EDT - 1 year ago

AnaptysBio Slides: Status Update

Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA

Jun 3, 2025, 4:05 PM EDT - 1 year ago

Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA

Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025

May 27, 2025, 4:15 PM EDT - 1 year ago

Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025

Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update

May 5, 2025, 4:15 PM EDT - 1 year ago

Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update

AnaptysBio Quarterly report: Q1 2025

May 5, 2025, 12:00 AM EDT - 1 year ago

AnaptysBio Quarterly report: Q1 2025

AnaptysBio Earnings release: Q1 2025

May 5, 2025, 12:00 AM EDT - 1 year ago

AnaptysBio Earnings release: Q1 2025

AnaptysBio Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

AnaptysBio Proxy statement: Proxy Filing

AnaptysBio Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

AnaptysBio Proxy statement: Proxy Filing

Anaptys Announces Stock Repurchase Plan

Mar 24, 2025, 9:15 AM EDT - 1 year ago

Anaptys Announces Stock Repurchase Plan

AnaptysBio Transcript: Barclays 27th Annual Global Healthcare Conference

Mar 12, 2025, 8:30 AM EDT - 1 year ago

AnaptysBio Transcript: Barclays 27th Annual Global Healthcare Conference

AnaptysBio Slides: Barclays 27th Annual Global Healthcare Conference

Mar 12, 2025, 8:30 AM EDT - 1 year ago

AnaptysBio Slides: Barclays 27th Annual Global Healthcare Conference

AnaptysBio Transcript: Leerink’s Global Healthcare Conference 2025

Mar 11, 2025, 10:40 AM EDT - 1 year ago

AnaptysBio Transcript: Leerink’s Global Healthcare Conference 2025

AnaptysBio Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 4, 2025, 1:10 PM EST - 1 year ago

AnaptysBio Transcript: TD Cowen 45th Annual Healthcare Conference

Anaptys Announces Participation in March Investor Conferences

Feb 27, 2025, 4:15 PM EST - 1 year ago

Anaptys Announces Participation in March Investor Conferences

Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 27, 2025, 4:15 PM EST - 1 year ago

Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

AnaptysBio Annual report: Q4 2024

Feb 27, 2025, 4:00 PM EST - 1 year ago

AnaptysBio Annual report: Q4 2024

AnaptysBio Earnings release: Q4 2024

Feb 27, 2025, 4:00 PM EST - 1 year ago

AnaptysBio Earnings release: Q4 2024

AnaptysBio Transcript: Study Update

Feb 12, 2025, 8:30 AM EST - 1 year ago

AnaptysBio Transcript: Study Update

AnaptysBio Press release: Study Update

Feb 12, 2025, 8:30 AM EST - 1 year ago

AnaptysBio Press release: Study Update

AnaptysBio Slides: Study Update

Feb 12, 2025, 8:30 AM EST - 1 year ago

AnaptysBio Slides: Study Update

Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months

Feb 12, 2025, 7:30 AM EST - 1 year ago

Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months

Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025

Feb 11, 2025, 5:30 PM EST - 1 year ago

Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025

AnaptysBio Transcript: Guggenheim SMID Cap Biotech Conference

Feb 5, 2025, 1:00 PM EST - 1 year ago

AnaptysBio Transcript: Guggenheim SMID Cap Biotech Conference

Anaptys to Present at the Guggenheim SMID Cap Biotech Conference

Feb 3, 2025, 4:15 PM EST - 1 year ago

Anaptys to Present at the Guggenheim SMID Cap Biotech Conference

Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist

Feb 3, 2025, 7:30 AM EST - 1 year ago

Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist

AnaptysBio Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 14, 2025, 7:30 PM EST - 1 year ago

AnaptysBio Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

AnaptysBio Slides: FY 2025

Jan 14, 2025, 7:30 PM EST - 1 year ago

AnaptysBio Slides: FY 2025

Anaptys to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 7, 2025, 9:15 AM EST - 1 year ago

Anaptys to Present at the 43rd Annual J.P. Morgan Healthcare Conference

AnaptysBio to abandon eczema drug development after mid-stage trial failure

Dec 11, 2024, 10:20 AM EST - 1 year ago

AnaptysBio to abandon eczema drug development after mid-stage trial failure

AnaptysBio abandons eczema drug development after mid-stage trial failure

Dec 11, 2024, 8:42 AM EST - 1 year ago

AnaptysBio abandons eczema drug development after mid-stage trial failure

Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis

Dec 11, 2024, 8:30 AM EST - 1 year ago

Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis

AnaptysBio Transcript: 7th Annual Evercore ISI HealthCONx Conference

Dec 4, 2024, 1:45 PM EST - 1 year ago

AnaptysBio Transcript: 7th Annual Evercore ISI HealthCONx Conference

AnaptysBio Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 3, 2024, 2:30 PM EST - 1 year ago

AnaptysBio Transcript: Piper Sandler 36th Annual Healthcare Conference

AnaptysBio Transcript: Stifel 2024 Healthcare Conference

Nov 19, 2024, 1:50 PM EST - 1 year ago

AnaptysBio Transcript: Stifel 2024 Healthcare Conference

Anaptys Announces Participation in November and December Investor Conferences

Nov 5, 2024, 4:15 PM EST - 1 year ago

Anaptys Announces Participation in November and December Investor Conferences

Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update

Nov 5, 2024, 4:15 PM EST - 1 year ago

Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update

AnaptysBio Quarterly report: Q3 2024

Nov 5, 2024, 3:00 PM EST - 1 year ago

AnaptysBio Quarterly report: Q3 2024

AnaptysBio Earnings release: Q3 2024

Nov 5, 2024, 3:00 PM EST - 1 year ago

AnaptysBio Earnings release: Q3 2024

AnaptysBio Registration statement: Registration Filing

Nov 5, 2024, 7:00 AM EST - 1 year ago

AnaptysBio Registration statement: Registration Filing

AnaptysBio Slides: Corporate Presentation

Nov 4, 2024, 6:00 PM EST - 1 year ago

AnaptysBio Slides: Corporate Presentation

AnaptysBio Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 18, 2024, 9:45 AM EDT - 2 years ago

AnaptysBio Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

AnaptysBio Transcript: 2024 Wells Fargo Healthcare Conference

Sep 5, 2024, 10:15 AM EDT - 2 years ago

AnaptysBio Transcript: 2024 Wells Fargo Healthcare Conference

Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering

Aug 14, 2024, 5:00 AM EDT - 2 years ago

Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering

Anaptys Announces Second Quarter 2024 Financial Results and Provides Business Update

Aug 5, 2024, 4:15 PM EDT - 2 years ago

Anaptys Announces Second Quarter 2024 Financial Results and Provides Business Update

AnaptysBio Quarterly report: Q2 2024

Aug 5, 2024, 4:00 PM EDT - 2 years ago

AnaptysBio Quarterly report: Q2 2024

AnaptysBio Earnings release: Q2 2024

Aug 5, 2024, 4:00 PM EDT - 2 years ago

AnaptysBio Earnings release: Q2 2024

Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update

May 9, 2024, 4:15 PM EDT - 2 years ago

Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update

Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)

May 9, 2024, 4:10 PM EDT - 2 years ago

Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)

StockBraker
StockBraker Aug. 12 at 10:46 AM
$ANAB Estimated ER date is today AH. Estimated EPS Forecast: -$0.13 to -$0.22. PREVIOUS Report: Released Q1 2026 results on May 12, 2026, with an EPS of -$1.84. Last quarter they completed spin-off of First Tracks Biotherapeutics, Inc., its former biopharma operations business. Now exclusively manages the financial collaborations for Jemperli with GSK and imsidolimab with Vanda. Personally looking for $100+/share LT. Those that have held for awhile have definitely benefited from the spinoff. BTW - If you need to know your cost basis for each company (ANAB, TRAX) for tax purposes you can either use what your broker states or Form 8937 (https://ir.anaptysbio.com/irs-form-8937)
0 · Reply
Ramod
Ramod Aug. 7 at 12:35 PM
$ANAB I’m In
0 · Reply
StockBraker
StockBraker Aug. 5 at 2:13 PM
$TRAX $ANAB Need to break through the $105 combined price ceiling. I hate this overhang from the Tesaro lawsuit. Legal processes move too slow.
0 · Reply
Jt11111
Jt11111 Jul. 29 at 6:22 PM
$TRAX $ANAB solid Jemperil sales from gsk —$320MM keep ANAB royalty on track and this is a steal at $50. 1. H1 2026 Actual Sales (First Half) Q1 2026: £232 million ($313 million USD) Q2 2026: £248 million ($320 million USD) Total H1 2026: £480 million GBP (~$620 million USD)
1 · Reply
Jt11111
Jt11111 Jul. 29 at 3:21 PM
$ANAB solid Jemperil sales from gsk —$320MM keep royalty on track and this is a steal at $50. 1. H1 2026 Actual Sales (First Half) Q1 2026: £232 million ($313 million USD) Q2 2026: £248 million ($320 million USD) Total H1 2026: £480 million GBP (~$620 million USD)
0 · Reply
Nickman18
Nickman18 Jul. 27 at 2:23 PM
$ANAB $TRAX I've owned since 2019 with a price average of 20.66 just wanted to brag quickly
1 · Reply
JackDarwin
JackDarwin Jul. 22 at 10:51 AM
$ANAB Bullish Marubozu with good volume.
0 · Reply
StockBraker
StockBraker Jul. 20 at 8:16 PM
$ANAB Guess I need to do this again. Collected $1048 premium and kept my shares.
0 · Reply
StockBraker
StockBraker Jul. 20 at 8:06 PM
$ANAB marketbeat.com/instant-alerts/anaptysbio-nasdaqanab-shares-down-62-heres-why-2026-07-20/
0 · Reply
Jt11111
Jt11111 Jul. 20 at 6:17 PM
$ANAB wtf
0 · Reply
StockBraker
StockBraker Jul. 17 at 2:56 PM
$ANAB Trial ends today and having begun at 9:15 this morning, according to the Docket Schedule, may already have concluded. Someone must either know something or is speculating based on what was said at the trial. Final Ruling is not expected until 4Q26 at the earliest.
0 · Reply
Merlintrader
Merlintrader Jul. 17 at 12:13 AM
Vanda Pharmaceuticals $VNDA Stock Hub - EMA orphan opinion strengthens imsidolimab in GPP, but the FDA December 12 PDUFA stays the key binary. Global rights via AnaptysBio $ANAB https://www.merlintrader.com/vanda-pharmaceuticals-vnda-stock-hub/
0 · Reply
StockBraker
StockBraker Jul. 16 at 10:10 PM
$ANAB https://www.sahmcapital.com/news/content/is-anaptysbio-anab-undervalued-following-its-jemperli-royalty-appeal-and-gsk-trial-2026-07-15
0 · Reply
StockBraker
StockBraker Jul. 16 at 12:35 PM
$ANAB Tomorrow will be last day of the trial for AnaptysBio vs Tesaro (GSK). A ruling will take some time. The impending ruling will decide the main remaining claims of the dispute: License Reversion: The court will determine if GSK/Tesaro materially breached their contract. If they did, the commercial license for Jemperli could revert entirely back to AnaptysBio. Exclusivity Claims: The judge will rule on whether GSK violated exclusivity terms by evaluating rival checkpoint inhibitors (like Keytruda) instead of maximizing Jemperli's commercial value.
0 · Reply
StockBraker
StockBraker Jul. 15 at 12:13 PM
$ANAB Today's Docket in the Delaware Court of Chancery. Continues through Friday unless an early decision or settlement is reached. https://courts.delaware.gov/chancery/
0 · Reply
StockBraker
StockBraker Jul. 15 at 11:16 AM
$ANAB dropped by roughly 7% due to profit-taking and the unwinding of short-term gains, compounded by recent insider selling and a wider-than-expected first-quarter loss of -$1.84 per share. The selloff occurred alongside a pullback in the broader biotechnology sector and institutional trading adjustments following the company's removal from several Russell indices. Despite the single-session pullback, broader Wall Street sentiment remains constructive. Analyst consensus sits at a "Moderate Buy" with an average price target of $81.82, as investors continue to look toward the ongoing legal developments regarding their Jemperli commercial agreements.
0 · Reply
MikeyMcDermott
MikeyMcDermott Jul. 14 at 11:49 PM
$ANAB reacting to the start of GSK lawsuit & no settlement Jemperli license dispute
0 · Reply
StockBraker
StockBraker Jul. 14 at 9:50 PM
$ANAB $72 -> $62 groan
1 · Reply
Jt11111
Jt11111 Jul. 14 at 5:37 PM
$ANAB thought the stock would respond to this news from GSK—small market but significant as patients may avoid any and all chemo and/or surgery: https://www.gsk.com/en-gb/media/press-releases/jemperli-dostarlimab-achieves-sustained-clinical-complete-responses-in-dmmrmsi-h-locally-advanced-rectal-cancer/
0 · Reply
StockBraker
StockBraker Jul. 14 at 2:43 AM
$ANAB Should be an interesting week ahead. AnaptysBio and GSK (via its subsidiary Tesaro) are currently locked in an ongoing contract dispute and countersuits over the blockbuster cancer immunotherapy Jemperli (dostarlimab). The dispute is scheduled for a trial in the Delaware Chancery Court from July 14–17, 2026
1 · Reply
StockBraker
StockBraker Jul. 13 at 11:28 PM
$ANAB Nov 20 $100 strike covered call is paying minimum $2.30 per contract.
0 · Reply
MikeyMcDermott
MikeyMcDermott Jul. 12 at 6:40 PM
I'm not sure if $ANAB or $GSK have any reason to settle Jemperli dispute before the trial on July 14. I can't see a full reversion of Jemperli back to ANAB. I can't see the royalty rate jacked up any higher, currently tiered up to 25% over $2.5 billion revs. There is well established rule of thumb in patent disputes that hypothetical profits are split 75% to the licensee who bears commercialization risk and 25% to the licensor who bears no risk (except for maximizing licensed sales). So are ANAB and GSK going to fight over a royalty on the therapy being used in combination with Keytruda and/or a small upfront payment like their 2020 litigation?
0 · Reply